Sunnyvale, CA, May 18, 2018 – BridGene Biosciences, Inc., a biomedical company based on novel and high-throughput chemical proteomic platform, announced the formation of its Scientific Advisory Board (SAB) and had the 1st SAB meeting with three key appointments: Kevan Shokat, Ph.D., Arthur Weiss, M.D., Ph.D., and Chao Zhang, Ph.D., who is the scientific founder of the company, and will serve as the Chairman of the SAB.
The SAB will work closely with the BridGene Biosciences management team to provide governance, oversight and advice to BridGene’s Sciences R&D team. The distinguished member of the SAB will bring deep relevant experience in medical science and pharmaceutical development. It will form a key strategic resource for the company, bringing unique perspectives and additional expertise to guide internal drug development programs and explore external collaborations.
Professor Kevan Shokat is currently an Investigator of the Howard Hughes Medical Institute, former Chair of the Department of Cellular and Molecular Pharmacology at the University o f California at San Francisco. He is also a Professor in the Department of Chemistry at the University of California at Berkeley. After receiving his Ph.D. in Organic Chemistry at UC Berkeley with Professor Peter Schultz, and postdoctoral work in immunology at Stanford University with Professor Chris Goodnow, Kevan began his independent research career at Princeton University where he was promoted from Assistant to Associate Professor in four years. He has received numerous awards including being named a Fellow of several prestigious research foundations including the Pew Foundation, Searle Foundation, Sloan Foundation, Glaxo-Wellcome Foundation, and the Cotrell Foundation. He has also received the Eli Lilly Award, given to the most promising biological chemist in the country under the age of 37. Dr. Shokat is a member of National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences.
Professor Arthur Weiss is currently an Investigator of the Howard Hughes Medical Institute, and Ephraim P. Engelman Distinguished Professor of Rheumatology at the University of California, San Francisco. Dr. Weiss received his Ph.D. (Immunology, 1978) and M.D. (1979) degrees from the University of Chicago. He did a postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research in Lausanne, Switzerland. Dr. Weiss completed his training in internal medicine and rheumatology at UCSF. In 1985, he joined the faculty of the Division of Rheumatology and the Howard Hughes Medical Institute at the University of California, San Francisco. His major academic activities include directing his research laboratory as well as serving as Chief of the Division of Rheumatology and as Director of the Medical Scientist Training Program. Dr. Weiss was president of The American Association of Immunologists from 2008 to 2009 and served on the AAI Council from 2003 to 2008. He was awarded the AAI Lifetime Achievement Award in 2012, the AAI-Life Technologies Meritorious Career Award in 2002, and the AAI-BD Biosciences Investigator Award in 1993. Dr. Weiss is a member of the National Academy of Sciences, Institute of Medicine and the American Academy of Arts and Sciences.
About BridGene Biosciences
BridGene is a biotechnology company dedicated to discovering novel targets and developing new therapeutics for unmet medical needs. BridGene is applying its IMTAC (Isobaric Mass Tagged Affinity Characterization) platform to discover druggable opportunities across the entire proteome. With IMTAC, BridGene is able to expand the therapeutic applications of small molecules drugs to a wider range of fields.